Advanced Molecular Characterization Using Digital Spatial Profiling Technology on Immunooncology Targets in Methylated Compared with Unmethylated IDH-Wildtype Glioblastoma

Table 1

Mean (SD) log 2 housekeeping normalised values by location and MGMT status.

Immunooncology targets and controls	Tumour core		Tumour margin
	Methylated	Unmethylated	Methylated	U nmethylated
	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)
CD4	11.22 (0.65)	9.58 (1.01)	10.16 (0.84)	9.68 (0.99)
CD14	12.58 (1.61)	9.47 (1.46)	10.79 (1.07)	9.75 (1.31)
CD68	12.97 (1.00)	11.14 (0.80)	12.32 (1.14)	11.67 (1.29)
CD8A	8.30 (0.78)	6.90 (0.66)	8.06 (0.82)	7.70 (0.68)
B7-H3	14.07 (1.02)	12.35 (0.87)	12.70 (0.94)	12.52 (1.44)
PD-L1	11.50 (0.57)	10.62 (0.58)	11.47 (0.51)	11.65 (0.77)
CD19	7.77 (0.74)	6.66 (0.63)	7.47 (0.37)	7.67 (0.87)
FOXP3	7.94 (0.73)	7.02 (0.51)	7.75 (0.58)	7.88 (0.76)
CD44	15.58 (1.24)	13.30 (1.60)	13.51 (1.49)	14.80 (2.61)
STAT3 (phospho Y705)	9.41 (0.61)	8.64 (0.53)	8.52 (0.51)	9.06 (1.03)
CD45	9.19 (1.00)	7.93 (0.83)	8.25 (0.83)	8.83 (1.44)
Pan Cytokeratin	9.11 (0.67)	8.43 (0.31)	8.92 (0.30)	9.35 (0.82)
MS4A1.CD20.	7.26 (0.63)	6.47 (0.53)	7.15 (0.65)	7.50 (0.69)
CD45RO	8.29 (0.81)	7.48 (0.50)	7.88 (0.39)	8.28 (0.92)
S6	13.64 (0.30)	13.21 (0.39)	13.60 (0.32)	13.27 (0.46)
PD1	8.08 (0.73)	7.43 (0.44)	7.47 (0.72)	7.87 (0.79)
CD3	8.90 (0.61)	8.04 (1.02)	9.28 (0.70)	9.17 (1.00)
Beta-2 microglobulin	13.80 (1.12)	12.91 (0.53)	13.78 (0.69)	13.33 (1.02)
VISTA	11.94 (0.70)	11.42 (0.77)	11.80 (0.45)	12.13 (1.59)
Bcl2	10.22 (0.84)	9.70 (0.50)	9.93 (0.32)	10.51 (1.12)
GZMB	10.65 (0.47)	10.27 (0.60)	10.68 (0.68)	10.73 (0.46)
PTEN	11.29 (1.11)	10.56 (1.08)	11.13 (0.59)	11.99 (1.57)
Beta-catenin	16.19 (0.66)	16.61 (0.51)	16.53 (0.52)	17.65 (0.72)
CD56	18.40 (0.98)	17.73 (1.37)	19.26 (0.91)	19.15 (1.33)
Ki-67	11.72 (1.76)	10.81 (1.27)	10.83 (0.99)	9.96 (1.49)
STAT3	12.85 (1.44)	13.24 (0.87)	12.95 (0.83)	13.32 (0.89)
AKT	14.57 (0.68)	14.55 (0.59)	15.06 (0.56)	14.82 (1.00)
P-Akt	11.21 (0.61)	11.24 (1.46)	11.51 (0.95)	12.14 (1.16)